<DOC>
	<DOCNO>NCT01035645</DOCNO>
	<brief_summary>GSK1070806 humanise monoclonal antibody block protein present body call Interleukin-18 . The main purpose study test GSK1070806 healthy obese male subject normal immune system find safe drug long body take get rid . The study consist 2 part . Part 1 consist 6 group healthy male subject Part 2 consist 3 group obese male subject . A total 89 subject plan study . Subjects group receive one dose study drug placebo . Dosing Part 2 start dose first 4 group complete Part 1 preliminary safety pharmacokinetic data 4 group Part 1 reviewed . Both part conduct single-blind placebo control . Within group , allocation subject placebo active treatment ( GSK1070806 ) randomise .</brief_summary>
	<brief_title>First Time Human Study Intravenous Interleukin-18 Antibody</brief_title>
	<detailed_description />
	<mesh_term>Inflammatory Bowel Diseases</mesh_term>
	<mesh_term>Antibodies</mesh_term>
	<mesh_term>Immunoglobulins</mesh_term>
	<mesh_term>Antibodies , Monoclonal</mesh_term>
	<criteria>Males age 1865 year inclusive time signing informed consent . Subjects must agree use one contraception method require . Capable give write informed consent , include compliance requirement restriction list consent form . Available complete study assessment . Able read , comprehend write English sufficient level complete study related material . Healthy determine responsible experienced physician . Positive delayed type hypersensitivity ( DTH ) reaction candida antigen within 72 hr screen visit ( group 4 , 8 9 subject Part 1 ) . Body weight equal great 50kg BMI within range 1929.9kg/m2 ( Part 1 ) . BMI within range 30 40kg/m2 ( Part 2 ) . Waist circumference &gt; 102cm ( Part 2 ) . Fasting plasma insulin &gt; 60pmol/L ( Part 2 ) . A positive prestudy Hepatitis B surface antigen positive Hepatitis C antibody result within 3 month screen . A positive prestudy drug/alcohol screen . A positive test HIV antibody . A positive test influenza A/B . A positive test Mycobacterium tuberculosis . History regular alcohol consumption within 6 month study define average weekly intake &gt; 21 unit average daily intake &gt; 3 unit . One unit equivalent 8 g alcohol , follow use guide : halfpint ( ~240 ml ) beer , 1 glass ( 125 ml ) wine 1 ( 25 ml ) measure spirit . The subject unwilling abstain alcohol consumption 24 hr prior dose discharge clinic , 24 hr prior outpatient clinic visit . The subject participate clinical trial receive investigational product within following time period prior first dose day current study : 90 day , 5 halflives twice duration biological effect investigational product ( whichever longer ) . Exposure four new chemical entity within 12 month prior first dose day . Subject receive live , attenuated recombinant vaccine ( ) within 2 month randomisation require vaccination prior time plasma level predict reach average level approximately 1.0 µg/mL dose administer Day 56 whichever longer . Current evidence , history within last 7 day , influenzalike illness define fever ( &gt; 38°C ) two follow symptom : cough , sore throat , runny nose , sneeze , limb / joint pain , headache , vomit / diarrhoea absence know cause , influenza . Use antiTumor Necrosis Factor ( antiTNF ) antiInterleukin1 ( antiIL1 ) drug within 60 day prior dose . Current evidence ongoing acute infection , history repeat , chronic opportunistic infection ( e.g . recurrent folliculitis , cutaneous infection repeat pneumonia ) history serious bacterial infection within 6 month randomisation . History significant cardiac , pulmonary , metabolic , renal , hepatic , gastrointestinal condition opinion study physician and/or GSK physician , place subject unacceptable risk participant trial . History Mycobacterium tuberculosis previous Mycobacterium infection . Use prescription nonprescription drug , include vitamin , herbal dietary supplement ( include St John 's Wort ) within 7 day 5 halflives ( whichever longer ) prior first dose study medication , unless opinion study physician GSK physician medication interfere study procedure compromise subject safety . History sensitivity study medication , component thereof history drug allergy , opinion study physician GSK physician contraindicate participation . Current chronic ( great 3 month ) treatment prescription antiinflammatory drug , include corticosteroid nonsteroidal antiinflammatory drug . History severe allergic reaction , angioedema , anaphylaxis immunodeficiency . History malignancy , except adequately treated noninvasive cancer skin ( basal squamous cell ) ( &gt; 2 yr prior dose ) . Subject whose calculated creatinine clearance le 80 mL/min Where participation study would result donation blood blood product excess 500 mL within 56 day period . Subject unable refrain travel country high prevalence infectious disease dose administered time plasma concentration GSK1070806 predict average approximately 1.0µg/mL dose administer Day 56 whichever longer . Unwillingness inability follow procedure outline protocol . Subject mentally legally incapacitate . Liver function test upper limit normal screening ( alkaline transaminase ( ALT ) , aspartate transaminase ( AST ) bilirubin ) ( Part 1 subject ) . Liver function test 2 x upper limit normal screening ( alkaline transaminase ( ALT ) , aspartate transaminase ( AST ) ) 1.5 x upper limit normal ( bilirubin ) ( Part 2 subject ) . Corrected QT interval ( QTc ) &gt; 450 msec . Subjects asthma history asthma , COPD pneumonia ( Note : subject suffer childhood asthma adult may include provide fulfil entry criterion . ) Subject symptomatic herpes zoster infection within 3 month randomisation . Subjects smoke history &gt; 10 cigarette per day last 3 month . Experiencing clinically significant ECG abnormality screen baseline . History elevate blood pressure current systolic blood pressure &gt; 140mmHg diastolic blood pressure &gt; 90mmHg . ( Part 1 ) . Has fast plasma glucose value equal great 7 mmol/L screen baseline , diagnose Type 1 Type 2 diabetes mellitus ( Part 2 ) Has fast triglyceride level &gt; 4.52 mmol/L screen baseline . Triglyceride level within 510 % margin level consider casebycase basis ( Part 2 ) . Subjects currently receive weight loss treatment , limit : `` crash '' /starvation diet ( e.g . &lt; 800ckal/day ) , ALLI™ ( Orlistat ) , Ephedra ( mahuang ) ephedrine base treatment , Cascara herbal treatment , opinion investigator and/or GSK Medical Monitor , contraindicate subject 's participation . Subjects must participate weight loss treatment outline course study ( Part 2 ) . Subjects plan substantial change diet course study ( Part 2 ) . Subjects participate weight loss treatment outline within 4 week randomisation ( Part 2 ) . Systolic blood pressure &gt; 150mmHg diastolic blood pressure &gt; 90mmHg screening ( Part 2 ) .</criteria>
	<gender>Male</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>November 2016</verification_date>
	<keyword>First time human</keyword>
	<keyword>Interleukin-18</keyword>
	<keyword>Healthy male subject</keyword>
	<keyword>Obese male subject</keyword>
	<keyword>Monoclonal antibody</keyword>
	<keyword>Pharmacokinetics</keyword>
	<keyword>Tolerability</keyword>
	<keyword>Safety</keyword>
	<keyword>Pharmacodynamics</keyword>
</DOC>